164 related articles for article (PubMed ID: 23853055)
1. Prostate cancer imaging trends after a nationwide effort to discourage inappropriate prostate cancer imaging.
Makarov DV; Loeb S; Ulmert D; Drevin L; Lambe M; Stattin P
J Natl Cancer Inst; 2013 Sep; 105(17):1306-13. PubMed ID: 23853055
[TBL] [Abstract][Full Text] [Related]
2. Regional-Level Correlations in Inappropriate Imaging Rates for Prostate and Breast Cancers: Potential Implications for the Choosing Wisely Campaign.
Makarov DV; Soulos PR; Gold HT; Yu JB; Sen S; Ross JS; Gross CP
JAMA Oncol; 2015 May; 1(2):185-94. PubMed ID: 26181021
[TBL] [Abstract][Full Text] [Related]
3. Quantifying downstream impact of inappropriate staging imaging in a cohort of veterans with low- and intermediate-risk incident prostate cancer.
Drangsholt S; Walter D; Ciprut S; Lepor A; Sedlander E; Curnyn C; Loeb S; Malloy P; Winn AN; Makarov DV
Urol Oncol; 2019 Feb; 37(2):145-149. PubMed ID: 30578160
[TBL] [Abstract][Full Text] [Related]
4. Re: prostate cancer imaging trends after a nationwide effort to discourage inappropriate prostate cancer imaging.
Taneja SS
J Urol; 2014 May; 191(5):1287-8. PubMed ID: 24745486
[No Abstract] [Full Text] [Related]
5. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial.
Nordström T; Discacciati A; Bergman M; Clements M; Aly M; Annerstedt M; Glaessgen A; Carlsson S; Jäderling F; Eklund M; Grönberg H;
Lancet Oncol; 2021 Sep; 22(9):1240-1249. PubMed ID: 34391509
[TBL] [Abstract][Full Text] [Related]
6. Effects of prostate-specific antigen testing on familial prostate cancer risk estimates.
Bratt O; Garmo H; Adolfsson J; Bill-Axelson A; Holmberg L; Lambe M; Stattin P
J Natl Cancer Inst; 2010 Sep; 102(17):1336-43. PubMed ID: 20724726
[TBL] [Abstract][Full Text] [Related]
7. An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection.
Vickers AJ; Till C; Tangen CM; Lilja H; Thompson IM
J Natl Cancer Inst; 2011 Mar; 103(6):462-9. PubMed ID: 21350221
[TBL] [Abstract][Full Text] [Related]
8. Effect of the USPSTF Grade D Recommendation against Screening for Prostate Cancer on Incident Prostate Cancer Diagnoses in the United States.
Barocas DA; Mallin K; Graves AJ; Penson DF; Palis B; Winchester DP; Chang SS
J Urol; 2015 Dec; 194(6):1587-93. PubMed ID: 26087383
[TBL] [Abstract][Full Text] [Related]
9. Five-year downstream outcomes following prostate-specific antigen screening in older men.
Walter LC; Fung KZ; Kirby KA; Shi Y; Espaldon R; O'Brien S; Freedland SJ; Powell AA; Hoffman RM
JAMA Intern Med; 2013 May; 173(10):866-73. PubMed ID: 23588999
[TBL] [Abstract][Full Text] [Related]
10. Gleason inflation 1998-2011: a registry study of 97,168 men.
Danneman D; Drevin L; Robinson D; Stattin P; Egevad L
BJU Int; 2015 Feb; 115(2):248-55. PubMed ID: 24552193
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study.
Rider JR; Sandin F; Andrén O; Wiklund P; Hugosson J; Stattin P
Eur Urol; 2013 Jan; 63(1):88-96. PubMed ID: 22902040
[TBL] [Abstract][Full Text] [Related]
12. Impact of choosing wisely on imaging in men with newly diagnosed prostate cancer.
Lange SM; Choudry MM; Hunt TC; Ambrose JP; Haaland BA; Lowrance WT; Hanson HA; O'Neil BB
Urol Oncol; 2023 Jan; 41(1):48.e19-48.e26. PubMed ID: 36307366
[TBL] [Abstract][Full Text] [Related]
13. Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005.
Adolfsson J; Garmo H; Varenhorst E; Ahlgren G; Ahlstrand C; Andrén O; Bill-Axelson A; Bratt O; Damber JE; Hellström K; Hellström M; Holmberg E; Holmberg L; Hugosson J; Johansson JE; Petterson B; Törnblom M; Widmark A; Stattin P
Scand J Urol Nephrol; 2007; 41(6):456-77. PubMed ID: 17934985
[TBL] [Abstract][Full Text] [Related]
14. Temporal trends in cause of death among Swedish and US men with prostate cancer.
Epstein MM; Edgren G; Rider JR; Mucci LA; Adami HO
J Natl Cancer Inst; 2012 Sep; 104(17):1335-42. PubMed ID: 22835388
[TBL] [Abstract][Full Text] [Related]
15. A clinician-centred programme for behaviour change in the optimal use of staging investigations for newly diagnosed prostate cancer.
Rutledge AB; McLeod N; Mehan N; Regan TW; Ainsworth P; Chong P; Doyle T; White M; Sanson-Fisher RW; Martin JM
BJU Int; 2018 May; 121 Suppl 3():22-27. PubMed ID: 29359883
[TBL] [Abstract][Full Text] [Related]
16. Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study.
Grönberg H; Adolfsson J; Aly M; Nordström T; Wiklund P; Brandberg Y; Thompson J; Wiklund F; Lindberg J; Clements M; Egevad L; Eklund M
Lancet Oncol; 2015 Dec; 16(16):1667-76. PubMed ID: 26563502
[TBL] [Abstract][Full Text] [Related]
17. Trends for Stage and Grade Group of Prostate Cancer in the US (2010-2016).
Schmanke K; Okut H; Ablah E
Urology; 2021 Mar; 149():110-116. PubMed ID: 33227304
[TBL] [Abstract][Full Text] [Related]
18. Variation in Prostate-Specific Antigen Testing Rates and Prostate Cancer Treatments and Outcomes in a National 20-Year Cohort.
Bergengren O; Westerberg M; Holmberg L; Stattin P; Bill-Axelson A; Garmo H
JAMA Netw Open; 2021 May; 4(5):e219444. PubMed ID: 33999165
[TBL] [Abstract][Full Text] [Related]
19. Reducing unnecessary biopsies while detecting clinically significant prostate cancer including cribriform growth with the ERSPC Rotterdam risk calculator and 4Kscore.
Verbeek JFM; Bangma CH; Kweldam CF; van der Kwast TH; Kümmerlin IP; van Leenders GJLH; Roobol MJ
Urol Oncol; 2019 Feb; 37(2):138-144. PubMed ID: 30528698
[TBL] [Abstract][Full Text] [Related]
20. Early-stage prostate cancer, PSA screening rates decline.
Printz C
Cancer; 2016 Mar; 122(6):825. PubMed ID: 26938268
[No Abstract] [Full Text] [Related]
[Next] [New Search]
